Medindia

X

Cystic Fibrosis Drug by Pharmaxis Requires Another Trial to Get FDA Approval

by Raja Nandhini on  March 21, 2013 at 7:32 AM Drug News   - G J E 4
FDA has denied approval to market the drug, Bronchitol, manufactured by the Australian biotechnology company, Pharmaxis, in US market.
 Cystic Fibrosis Drug by Pharmaxis Requires Another Trial to Get FDA Approval
Cystic Fibrosis Drug by Pharmaxis Requires Another Trial to Get FDA Approval
Advertisement

The dry powder formulation of mannitol (Bronchitol) is designed to treat cystic fibrosis. It is approved in Australia for patients above six years of age and for adults above 18 years old in European Union.

Advertisement
The review committee has rejected the approval stating that an additional trial is required to prove the efficacy of the drug. FDA has noted that the first two clinical trial data submitted by the company do not meet benefit- risk balance. The first trial had too many early dropouts while the second study failed to produce statistically significant results.

Gary Phillips, CEO of Pharmaxis has announced that the company is ready to work with FDA and take the required measured to gain approval.

Source: Medindia
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All